GRAL GRAIL, Inc. Common Stock Загрузка... : Бычьи и медвежьи мнения аналитиков

Загрузка графика...
Лучшие сигналы
Лента
Загрузка...
Загрузка...
Загрузка...
Загрузка...
Загрузка...
Загрузка...
Весь контент
Ленты источников
Buzzberg Топ 50
Все капитализацииБез фильтра по капитализации
200 млрд и вышеМега
от 10 до 200 млрдКрупные
от 2 до 10 млрдСредние
от 0 до 2 млрдМалые
Свой
Введите диапазон капитализации в млрд USD
Все направления
▲ Лонг
▼ Шорт
⛔ Избегать
✂ Закрытие
◦ Другие
Любая оценка
Низкая+
Средняя+
Высокая
? ?
23:42
26 июн
The author notes that GRAL is a spin-off from ILMN.
The author notes that GRAL is a spin-off from ILMN, providing factual context without expressing a directional view on either ticker.
GRAL
Низ.
19:33
04 июн
The author asks a brief question about GRAL in response to news on lung cancer detection.
The author asks a brief question about GRAL in response to news on lung cancer detection proteins, without stating a position.
GRAL
Низ.
02:00
28 мая
The tweet notes a clean breakout in GRAL in hindsight.
The tweet notes a clean breakout in GRAL in hindsight, but lacks a forward-looking opinion or trade call, making it a factual observation.
GRAL
Низ.
20:08
06 мая
Reports good earnings for GRAL and observes price breakout from consolidation.
Reports good earnings for GRAL and observes price breakout from consolidation, no directional commitment.
GRAL
Низ.
09:42
05 мая
Grail test FDA-rejected, high false positive rate
Short Grail — its flagship cancer screening test lacks FDA approval due to an unacceptably high false positive rate, meaning the core product is clinically unreliable and commercially impaired; the business case rests on a test that is "more wrong than right."
GRAL 1-й
Сред.
08:30
10 фев
Quest provides phlebotomy logistics for Grail's multi-cancer early detection test, representing a modest but growing revenue stream and validating Grail's clinical deployment.
GRAL
Выс.
19:15
09 фев
Buy GRAL on multiple converging catalysts — HIMS partnership, FDA approval progress.
Buy GRAL on multiple converging catalysts — HIMS partnership, FDA approval progress, and supportive legislation — with speaker viewing $100 as new support after missing a lower re-entry, implying continued upside from current levels.
GRAL 1-й
Сред.

Об аналитическом покрытии GRAL

Buzzberg отслеживает GRAL (GRAIL, Inc. Common Stock) в 3 источниках. Бычьих сигналов: 1, медвежьих: 1, от 3 аналитиков. Сентимент разделён поровну. Всего отслеживается 7 торговых идей. Последние спикеры: incomesharks, CryptoCondom, Jim Davis.